Johnson & Johnson Asks FDA To Authorize Vaccine

Johnson & Johnson has applied for emergency use authorization for its COVID vaccine, which requires only a single dose and can be stored in regular refrigerators. This vaccine is 66% effective against moderate and severe COVID cases, which is lower than Pfizer and Moderna's 95% efficacy. However, its logistical advantages and complete protection against hospitalizations and deaths 28 days post-vaccination make it a strong contender, especially for vaccinating hard-to-reach populations.

Why might the Johnson and Johnson vaccine be particularly useful for hard-to-reach populations?

What is the significance of the Johnson and Johnson vaccine providing complete protection against COVID-related hospitalizations and deaths?